

A Lesser Known Side Effect of Tigecycline: Hypofibrinogenemia

Tigesiklinin Daha Az Bilinen Bir Yan Etkisi: Hipofibrinojenemi

© Fulya Yılmaz Duran, © Halil Yıldırım, © Emre Mehmet Şen

Bozyaka Training and Research Hospital, Clinic of Anesthesiology and Reanimation, İzmir, Turkey

To the Editor,

Fibrinogen is a soluble protein that is produced in hepatocytes. It participates in blood coagulation and is considered as an acute phase protein with a half-life of 3 to 4 days [1,2]. Fibrinogen values range from 200 to 400 mg/dL [1,3]. While hyperfibrinogenemia is correlated with systemic inflammation and malignancy, hypofibrinogenemia can be observed in chronic inherited diseases, acquired hepatic dysfunction, severe malnutrition, disseminated intravascular coagulation, abnormal fibrinolysis, large volumes of blood transfusions, and drug administration [1,3,4].

Tigecycline is the first member of the glycylcyclines. This is a new class of drugs structurally similar to tetracyclines [1,5,6]. It can be used to treat complicated intraabdominal infections, complicated skin infections, and community-acquired bacterial pneumonia [6,7]. Tigecycline inhibits protein synthesis by binding to the 30S ribosomal subunit and blocking entry of aminoacyl-transfer RNA molecules into the A side of the ribosome [1,2]. It has poor bioavailability and so requires intravenous administration with a loading dose of 100 mg, followed by 50 mg twice daily [1,6]. In patients with child C cirrhosis, the manufacturer suggests a reduced dose (25 mg twice daily) [5]. Multiple adverse events have been reported [1]. A decrease in fibrinogen levels has been observed and severe coagulopathy has also been reported during tigecycline treatment [2,6].

A 90-year-old female patient was admitted to the emergency department with the complaint of nausea and vomiting for 3 days. Her medical history included asthma and chronic renal failure. Physical examination revealed respiratory failure, unconsciousness, and bilateral rhonchi on chest auscultation. Computer tomography of the thorax revealed bilateral effusion, consolidation, and diaphragm hernia. She was intubated and transferred to the intensive care unit (ICU). The initial anti-infective regime consisted of piperacillin/tazobactam at 3x4.5 g and ciprofloxacin at 2x400 mg intravenously. On the 15th day of admission, the antibiotherapy was switched to tigecycline because of unresponsiveness to the first antibiotherapy.

On the 10th day of tigecycline therapy, a progressive worsening of hyperbilirubinemia was noted. Simultaneously, the hemoglobin level was markedly decreased (Table 1). To exclude hepatic or biliary pathology and abdominal pathology, abdominal ultrasonography was performed, followed by computed tomography, but they revealed no pathological entities. Moreover, fibrinogen was lower. As we suspected an association with the use of tigecycline, we discontinued the drug on the 10th day of therapy. After discontinuation of tigecycline, fibrinogen levels improved markedly within 8 days and bilirubin levels tended to be lower. On the 40th day of ICU admission, she died.

We hypothesized that the decrease in fibrinogen level was a side effect of tigecycline because hypofibrinogenemia became

Table 1. Laboratory findings of the patient.

	Tigecycline started	On 10 th day of tigecycline therapy (first)	On 10 th day of tigecycline therapy (second)	On 5 th day after tigecycline therapy cessation	On 8 th day after tigecycline therapy cessation	On 13 th day after tigecycline therapy cessation
Hemoglobin	11.3	6.3	4.9	10	9.5	8.6
Total bilirubin	0.56	1.27	1.44	19.05	18.4	14.7
Direct bilirubin	0.22	-	0.89	7.9	17.6	9
Fibrinogen levels	400	115	115	185	673	203
Platelets	282	310	259	116	121	183
INR	1.28	1.92	1.45	1.34	1.24	1.18
aPTT	31.1	62	45.7	38.2	34.2	34.5
PT	14.2	21.7	16.2	14.9	13.8	13.1

INR: International normalized ratio, aPTT: activated partial thromboplastin time, PT: prothrombin time.

apparent only after 10 days of antimicrobial therapy and the fibrinogen level increased after the withdrawal of tigecycline. Life-threatening coagulopathy and hypofibrinogenemia cases induced by tigecycline were reported by Rossitto et al. [5], Pieringer et al. [7], and Sabanis et al. [1]; clinical studies were reported by Routsis et al. [6] and Zhang et al. [2] in the literature. However, the main mechanism by which tigecycline provokes hypofibrinogenemia is ambiguous [1,5]. It could be by intestinal microflora or by hepatic dysfunction [1,5,7]. The posttranscriptional regulation of the fibrinogen gene by miRNAs could be the cornerstone in this field [1].

We suggest routine strict monitoring of coagulation parameters in patients receiving tigecycline. If patients develop hypofibrinogenemia, one should consider discontinuation of the drug.

Keywords: Hypofibrinogenemia, Tigecycline, Hemoglobine level

Anahtar Sözcükler: Hipofibrinojenemi, Tigesiklin, Hemoglobin seviyesi

Conflict of Interest: The authors of this paper have no conflicts of interest, including specific financial interests, relationships,

and/or affiliations relevant to the subject matter or materials included.

References

1. Sabanis N, Paschou E, Gavriilaki E, Kalaitzoglou A, Vasileiou S. Hypofibrinogenemia induced by tigecycline: a potentially life-threatening coagulation disorder. *Infect Dis (Lond)* 2015;47:743-746.
2. Zhang Q, Zhou S, Zhou J. Tigecycline treatment causes a decrease in fibrinogen levels. *Antimicrob Agents Chemother* 2015;59:1650-1655.
3. Martis N, Chirio D, Queyrel-Moranne V, Zenut MC, Rocher F, Fuzibet JG. Tocilizumab-induced hypofibrinogenemia: a report of 7 cases. *Joint Bone Spine* 2017;84:369-370.
4. Zhou HB. Hypofibrinogenemia caused by hemocoagulase after colon polyps excision. *Am J Case Rep* 2017;18:291-293.
5. Rossitto G, Piano S, Rosi S, Simioni P, Angeli P. Life-threatening coagulopathy and hypofibrinogenemia induced by tigecycline in a patient with advanced liver cirrhosis. *Eur J Gastroenterol Hepatol* 2014;26:681-684.
6. Routsis C, Kokkoris S, Douka E, Ekonomidou F, Karaikos I, Giamarellou H. High-dose tigecycline-associated alterations in coagulation parameters in critically ill patients with severe infections. *Int J Antimicrob Agents* 2015;45:90-93.
7. Pieringer H, Schmekal B, Biesenbach G, Pohanka E. Severe coagulation disorder with hypofibrinogenemia associated with the use of tigecycline. *Ann Hematol* 2010;89:1063-1064.



Address for Correspondence/Yazışma Adresi: Fulya YILMAZ DURAN, M.D.,
Bozyaka Training and Research Hospital, Clinic of Anesthesiology and Reanimation, İzmir, Turkey
Phone : +90 232 250 50 50
E-mail : drfulya@mynet.com ORCID-ID: orcid.org/0000-0002-6901-7404

Received/Geliş tarihi: August 16, 2017
Accepted/Kabul tarihi: December 06, 2017

DOI: 10.4274/tjh.2017.0310